Evidence map›Paper›PMID 28570625›Full record

ArticlePloS one2017

An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells.

Waqas Azeem, Margrete Reime Hellem, Jan Roger Olsen, Yaping Hua, Kristo Marvyin, Yi Qu, Biaoyang Lin, Xisong Ke, Anne Margrete Øyan, Karl-Henning Kalland

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Waqas AzeemDepartment of Clinical Science, University of Bergen, Bergen, Norway.ORCID http://orcid.org/0000-0001-7334-2464
Margrete Reime HellemDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Jan Roger OlsenDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Yaping HuaDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Kristo MarvyinDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Yi QuDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Biaoyang LinZhejiang California International NanoSystems Institute, Hangzhou, P.R. China.
Xisong KeDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Anne Margrete ØyanDepartment of Clinical Science, University of Bergen, Bergen, Norway.
Karl-Henning KallandDepartment of Clinical Science, University of Bergen, Bergen, Norway.
University of Bergen · NOHaukeland University Hospital · NOUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The androgen receptor (AR) transcription factor plays a key role in the development and progression of prostate cancer, as is evident from the efficacy of androgen-deprivation therapy, AR is also the most frequently mutated gene, in castration resistant prostate cancer (CRPC). AR has therefore become an even more attractive therapeutic target in aggressive and disseminated prostate cancer. To investigate mechanisms of AR and AR target gene activation in different subpopulations of prostate cancer cells, a toolkit of AR expressor and androgen response element (ARE) reporter vectors were developed. Three ARE reporter vectors were constructed with different ARE consensus sequences in promoters linked to either fluorescence or luciferase reporter genes in lentiviral vector backbones. Cell lines transduced with the different vectors expressed the reporters in an androgen-dependent way according to fluorescence microscopy, flow cytometry and multi-well fluorescent and luminescence assays. Interestingly, the background reporter activity in androgen-depleted medium was significantly higher in LNCaP cells compared to the prostate transit amplifying epithelial cell lines, EP156T-AR and 957E/hTERT-AR with exogenous AR. The androgen-induced signal to background was much higher in the latter benign prostate cells than in LNCaP cells. Androgen-independent nuclear localization of AR was seen in LNCaP cells and reduced ARE-signaling was seen following treatment with abiraterone, an androgen synthesis inhibitor. The ARE reporter activity was significantly stronger when stimulated by androgens than by β-estradiol, progesterone and dexamethasone in all tested cell types. Finally, no androgen-induced ARE reporter activity was observed in tumorigenic mesenchymal progeny cells of EP156T cells following epithelial to mesenchymal transition. This underscores the observation that expression of the classical luminal differentiation transcriptome is restricted in mesenchymal type cells with or without AR expression, and presence of androgen.

Indexed as

Genes, ReporterCell LineGreen Fluorescent ProteinsHumansMaleProstateReceptors, AndrogenTransfectionGreen Fluorescent ProteinsReceptors, Androgen

Identifiers

PMID28570625
PMCPMC5453475
OpenAlexW2621327486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.